Post-authorisation Safety Cohort Observation Of Retacrit (tm) (Epoetin Zeta) Administered Subcutaneously For The Treatment Of Renal Anaemia (Pasco Ii)

Trial Profile

Post-authorisation Safety Cohort Observation Of Retacrit (tm) (Epoetin Zeta) Administered Subcutaneously For The Treatment Of Renal Anaemia (Pasco Ii)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Epoetin zeta (Primary)
  • Indications Anaemia
  • Focus Adverse reactions
  • Acronyms PASCO II
  • Sponsors Hospira; Pfizer
  • Most Recent Events

    • 16 Jun 2017 Planned number of patients changed from 4500 to 6700.
    • 25 Apr 2017 Planned End Date changed from 30 Mar 2020 to 1 Apr 2022.
    • 25 Apr 2017 Planned primary completion date changed from 31 Jul 2018 to 1 Apr 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top